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A B S T R A C T
Delirium is a complex and multifactorial condition associated with long-term cognitive decline. Due to the strong
links between systemic inflammation, delirium and dementia we hypothesized that responses within the brain in
patients who develop delirium could show biochemical overlap with patients with Alzheimer’s disease (AD). In
this observational study we analyzed protein expression signatures in cerebrospinal fluid (CSF) from 15 patients
with infectious delirium and compared these to 29 patients with AD, 30 infectious patients without delirium and
15 non-infectious controls free of neurological disease. A proximity extension assay was performed measuring a
total of 184 inflammatory and neurology-related proteins. Eight inflammatory proteins (4%), including the key
neuron-microglia communication marker CX3CL1 (fractalkine), were significantly upregulated in both delirium
and AD, compared to infectious patients without delirium. Likewise, 23 proteins (13%) showed downregulation
in both delirium and AD, relative to infectious patients without delirium, which interestingly included CD200R1,
another neuron-microglia communication marker, as well as a cluster of proteins related to synapse formation
and function. Synaptopathy is an early event in AD and correlates strongly with cognitive dysfunction. These
results were partially mediated by aging, which is an important predisposing risk factor among many others for
both conditions. Within this study we report the first in vivo human evidence suggesting that synapse pathology
and loss of homeostatic microglial control is involved in the pathophysiology of both infectious delirium and AD
and thus may provide a link for the association between infections, delirium and long-term cognitive decline.
1. Introduction
Delirium is an acute mental disorder including fluctuating dis-
turbances in attention, awareness and cognition (American Psychiatric
Association, 2013), that is often accompanied by hallucinations, mis-
perceptions, delusions, anxiety, mood disorders and sleep disturbances
(American Psychiatric Association Work Group on Delirium, 1999).
Especially patients with predisposing factors such as advanced age,
comorbidities or a history of cognitive dysfunction are at risk (Fong
et al., 2009) but almost any individual can experience a delirious
episode if the stimulus is severe enough or when an intercurrent illness
is combined with other precipitating factors such as pain, anesthetics,
benzodiazepines or opiate use, sleep deprivation, among others (Inouye
et al., 2014). The overall prevalence in hospitalized medical patients
exceeds 10%, which rises to over 20% in elderly (> 65 years) and over
50% in intensive care units and postoperative hip fracture patients
(Cunningham and Maclullich, 2013). One of the main risk factors for
developing delirium is systemic inflammation, e.g. due to a pneumonia
or urinary tract infection.
Although delirium in patients with such an infection (“infectious
delirium”) was long regarded as a benign, transient condition, it is now
recognized to be associated with impaired short-term outcomes and
also with impaired long-term psychiatric and cognitive outcomes
(Jackson et al., 2014; Langan et al., 2017; Pandharipande et al., 2013;
van den Boogaard et al., 2012) and even increased risk to develop
dementia (Davis et al., 2012; Jackson et al., 2004; MacLullich et al.,
2009). It is believed that this risk is mediated through activation of
immune cells within the brain (neuroinflammation), caused by
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pro-inflammatory products from the circulation reaching the brain.
Indeed, neuroinflammation has been shown to play a role in both
systemic inflammation as well as in neurodegeneration (Heneka et al.,
2015; Hoogland et al., 2015; Lemstra et al., 2007; Ransohoff, 2016;
Sandiego et al., 2015). However, large knowledge gaps remain on
which biochemical pathways are dysregulated in the human brain
during systemic inflammation leading to delirium.
Previous studies showed that levels of inflammatory cytokines in
preoperatively obtained cerebrospinal fluid (CSF) was linked to
development of delirium (Hall et al., 2016; Neerland et al., 2016;
Westhoff et al., 2015). In another cohort of patients with heterogenous
causes for delirium, CSF proteomics showed dysregulated protein
expression related to a variety of different biological processes
including proteins related to inflammatory, apolipoprotein, hormone
and neurotransmission processes (Poljak et al., 2014). Combined these
data suggest a role not only for the inflammatory response as
component of delirium but also dysregulation of protein expression in
novel and unexpected clusters of proteins. Since most work has been
done with preoperative samples assessing expression changes
predisposing to the development of delirium, this warrants further
investigation during delirium itself. Thus far, no studies were conducted
during a homogenous cohort of infectious delirium.
Due to the strong associations between systemic inflammation and
development of both delirium and dementia we hypothesized that
responses within the brain in those patients who develop delirium
during a state of systemic inflammation could show spectrum overlap
with patients with AD. Therefore we performed an observational study
on CSF of patients with infectious delirium and analyzed protein
expression signatures using the novel proximity extension assay
technology. We compared results with patients that did not develop
delirium during a systemic infection in addition to patients with AD
(positive controls) and non-infectious controls free of neurological
disease.
2. Materials and methods
2.1. Selection of CSF samples
The Radboudumc Neurochemistry Laboratory is the Dutch national
reference center for diagnostics on cerebrospinal fluid. This laboratory
kindly provided a list of all stored remnant CSF samples of patients that
did not object to storage and further use for scientific purposes and
where the CSF was sampled in the years 2011–2016. All CSF samples
were collected in the same center in polypropylene tubes and processed
by the same lab with corresponding centrifugation and aliquot
protocols. The Regional Medical Ethics Committee (“CMO regio
Arnhem-Nijmegen”) approved the study protocol and waived the need
for additional informed consent. This study was conducted in
accordance to the Helsinki Declaration.
CSF samples were eligible from patients ≥18 years. Clinical
parameters were collected from the patients’ medical files. In infected
patients, the indication for the lumbar puncture was to rule out a
neurological focus of the infection. If ancillary investigations ruled out
the diagnosis of viral or bacterial meningitis or encephalitis, patients
were deemed suitable for inclusion. Samples were excluded from the
study if the patients met any of the following criteria: patients with
central nervous system (CNS) infection within the past 6 months,
patients with other neurological conditions such as brain injury within
the last 3 months, known brain tumors, neurodegenerative disease or
pre-existing cognitive impairment, brain or spinal surgery within the
last 3 months, presence of a CSF catheter or shunt, severe
immunosuppression (neutropenia or HIV) and chronic use of
neuroleptics. Delirium was diagnosed according to the DSM-IV or -5
criteria (American Psychiatric Association, 2000, 2013) and if no other
causes than the systemic infection for the delirium were present, the
diagnosis ‘infectious delirium’ was made.
Non-infectious controls were selected from the same database.
These patients were free from neurological disorders and underwent a
lumbar puncture mainly to exclude disorders (e.g. to rule out high
pressure or subarachnoidal hemorrhage in case of thunderclap
headache) and conventional diagnostic analysis did not show any
abnormalities. Patients with diseases associated with acute or chronic
systemic inflammation (e.g. infections, Crohn’s disease or psoriasis) in
their medical history were also excluded as controls.
To compare the samples from infectious patients with ‘positive’
controls in line with our hypothesis, patients with mild cognitive
impairment (MCI) (Clinical Dementia Rating (CDR) 0.5) with reported
progression to AD and patients with mild AD (CDR 1) at the time of the
lumbar puncture were selected. The diagnosis of MCI or mild AD was
based on neuropsychological and clinical evaluation, including CSF
analysis, prior to inclusion in the study and was made by a
multidisciplinary team led by AD specialized geriatricians according to
international diagnostic criteria. The subjects with MCI or mild
dementia were considered as one group with CDR > 0.
2.2. Proximity extension assay technology
Frozen CSF samples were stored in −80 °C and not thawed before.
Frozen aliquots of patient samples were shipped to Olink Bioscience
(Uppsala, Sweden) and analyzed there according to the laboratory’s
standard operating procedure. Olink Bioscience was blinded to the
diagnostic groups. Analyses were performed using the Olink Proseek®
Multiplex Inflammation I96×96 and the Olink Proseek® Multiplex
Neurology I96×96 panels, which measure both 92 selected inflammatory
and 92 neurological proteins respectively, amounting to a total number
of 184 measured proteins, requiring only 1 μl of sample. These panels
use a proximity extension assay (PEA) technology where 92
oligonucleotide-labeled antibody probe pairs are allowed to bind to
their respective target in the sample, resulting in a high specificity.
Results are reported in relative units referred to as normalized protein
expression (NPX) which is in a log2 scale. The limit of detection (LOD)
was defined as 3 standard deviations above background and values
below this limit were reported as< LOD. These were replaced by the
minimum value for that particular protein divided by two. Reported
values below zero were replaced by 0.0001. Proteins with a call
rate< 90% (i.e.< 90% of the patients had a valid measurement of that
protein) were removed from further analysis. To filter out for poorly
expressed proteins, only proteins with an average expression of at least
2 for one of the diagnosis groups was kept. Samples did not pass quality
control if Incubation Control 2 or Detection Control (corresponding to
that specific sample) deviated more than 0.3 from the median value of
all samples. A total of five samples did not pass quality control for the
Inflammation panel and the results from these patients were therefore
removed from the statistical analysis for the proteins in this panel. To
correct for systematic bias due to batch effects and differential total
protein content, all NPX values were z-transformed per patient.
2.3. AD biomarkers
To assess whether preclinical and prodromal AD pathology was
present in the infectious groups (with and without delirium) or in the
control group, amyloid-β (Aβ)1-40, amyloid-β (Aβ)1-42, total tau, and
phosphorylated tau at threonine 181 (p-tau) were determined
batchwise with a simultaneous luminex assay (Milliplex, Merck
Millipore, Billerica, USA). We calculated Aβ1-42/Aβ1-40 ratio’s.
2.4. Statistical analysis and bioinformatics
Results are reported as mean (± SD) if a normal distribution was
found using the Kolmogorov-Smirnov test. Non-parametric data is
expressed in median and interquartile range (IQR). The baseline
characteristics were tested between groups using one-way ANOVA or
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Kruskall Wallis test (if the data was non-parametric) for continuous
data and with Chi square test for categorical data.
To identify differentially expressed proteins, p-values and changes
in z-scores were calculated for each protein for each comparison
between diagnostic groups using an unpaired t-test. We calculated the
change in z-score and visualized the patterns of up- and downregulation
of proteins compared to non-infectious controls with a heatmap. We
corrected for multiple comparisons using the False Discovery Rate
(FDR) adjustment and the FDR-adjusted p-value for significance was
determined 0.05.
In order to account for age as a confounding factor between the
infectious groups with and without delirium, we performed sensitivity
analyses on a cohort of infectious patients without delirium which was
age-matched to the infectious delirium and AD cohort.
To assess which proteins cluster together, and might thus operate in
the same pathway, we analyzed proteins based on their expression
values using unsupervised hierarchical clustering with the ward
agglomeration method and Pearson’s correlation. To focus on relevant
proteins we only show proteins that have at least a correlation of 0.85
or higher with another protein and have at least an average expression
value of > 1 in one of the diagnosis groups.
Principal component analysis (PCA) was performed to identify
groups of CSF proteins that correlate to such an extent that they could
be summarized into one new variable (a component). These
components can be used to assess the coherence between proteins and
to assess the relation between clusters of proteins with clinical
parameters. PCA was performed on the z-scores of protein expression
levels using Varimax rotation, as we assume that latent constructs of
protein data may correlate and not be entirely independent.
In order to classify the biological significance of our findings we
downloaded the GeneOntology (GO) annotations for each differentially
expressed protein from QuickGO (Binns et al., 2009) and studied which
annotation/pathway was differentially expressed more than once.
Correlations with systemic inflammatory parameters temperature,
blood leukocyte counts and plasma C-reactive protein (CRP) were
assessed with Pearsons’s correlation and FDR adjustment was applied to
correct for multiple comparisons.
The analyses were performed using R, version 3.5.3 (http://www.R-
project.org) software packages and IBM Corp. IBM SPSS Statistics for
Windows, Version 22.0. (Armonk, NY: IBM Corp.). Figures were made
in GraphPad Prism version 5.03.
3. Results
3.1. Selection and baseline characteristics
Fig. 1 presents the selection of infectious patients with and without
delirium. We screened 8624 CSF samples for eligibility. We included 45
samples from patients that suffered from a systemic infection and where
an infectious focus within the CNS compartment was ruled out by
means of a lumbar puncture in addition to other ancillary testing.
(Fig. 1). Fifteen of these 45 patients had delirium at time of the lumbar
puncture. Additionally, 15 samples from non-infected controls and 29
samples from patients with mild AD were included. Demographic
characteristics are listed in Table 1. Patients with infectious delirium or
AD were significantly older than infectious patients without delirium
and the non-infected controls. Diabetes and renal disease were more
prevalent among delirium patients and hypertension was more
prevalent among AD patients. Infectious patients were more likely to
use immunosuppressive medication than the non-infectious controls
and AD patients.
It was only possible to calculate the Sepsis-related Organ Failure
Assessment (SOFA) score and the Acute Physiology and Chronic Health
Evaluation II (APACHE II) in 14 infectious patients of which only 5
patients in the group without delirium. We observed no relevant
differences in sepsis related organ failure and disease severity between
infectious delirium and infectious patients without delirium. Also, no
relevant difference in CSF/plasma albumin ratio between the groups
was observed in n = 47 samples, suggesting that blood-CSF barrier
integrity did not confound the CSF results. Freezer storage time
between sampling and analysis was higher in AD compared to
infectious patients with and without delirium, but all samples did not
undergo previous thawing.
Importantly, we found no overlap between AD and the other three
patient groups in the established CSF biomarkers for AD pathology.
Aβ1-42/Aβ1-40 ratio was significantly lower in AD patients, and total tau
and p-tau were significantly higher in AD patients compared to patients
with infectious delirium, to infectious patients without delirium, and to
non-infectious controls (Fig. 2). Amyloid ratios and tau levels did not
differ between the two infectious groups.
3.2. Proximity extension assay results
Thirty-one proteins were excluded because they were detected in
less than 90% of the samples. Importantly, none of these 31 removed
proteins showed significantly higher expression frequencies in one of
the patient groups and 20 were not expressed in any of the samples
(Supplementary Table 1). A total of 153 proteins was included in the
analyses. Fig. 3 presents the expression patterns relative to non-
infectious controls of 96 (63%) proteins that were significantly
differently expressed in at least one of the patient groups. Details on the
differences relative to non-infectious controls are described in the
supplemental file.
3.2.1. Similarities in expression patterns between infectious delirium and
mild AD
In the upper part of Fig. 3, 31 proteins with similar expression
patterns between infectious delirium and AD are depicted that show
contrasting expression in patients with infections without delirium.
Eight proteins were upregulated (shown in blue) in both infectious
delirium and AD and these upregulated proteins are mainly involved in
chemotaxis and cytokine activity. Also, the cytokine fractalkine
(CX3CL1), which is involved in neuron-microglia communication, was
upregulated in both patient groups.
Twenty-three proteins were downregulated (shown in red) in
infectious delirium and AD in contrast to the expression in patients with
infections without delirium. These include in order of change in z-score:
neuroblastoma suppressor of tumorigenicity (NBL1), Thy-1 membrane
glycoprotein (THY1), neuronal cell adhesion molecule (NrCAM),
neurocan core protein (NCAN), brevican core protein (BCAN), tumor
necrosis factor receptor super family member 21 (TNFRSF21) and
Delta- and Notch like epidermal growth factor-related receptor (DNER).
Many of these downregulated proteins are brain-related and involved in
axonal, dendritic, neuronal and synaptic pathways. Furthermore,
several downregulated proteins, including CD200R1, are associated
with immunological pathways. Fig. 4 illustrates the expression patterns
of proteins of particular interest in all four patient groups.
3.2.2. Similarities in expression patterns between infectious delirium and
infections without delirium
Thirty-four proteins showed a similar expression pattern between
infectious delirium and infectious patients without delirium, which
contrasted to patients with AD. These proteins are illustrated in the
bottom part of Fig. 3. All eight upregulated proteins (depicted in blue)
in both infectious conditions relative to AD are related to inflammation
and these include the pro-inflammatory proteins interleukin-6 (IL6) and
interleukin-8 (IL8) and the anti-inflammatory interleukin-10 (IL10).
Other inflammatory proteins like C-X-C motif chemokine 5 (CXCL5),
C-C motif chemokine 19 (CCL19), and urokinase-type plasminogen
activator (uPA) were downregulated (depicted in red) in both infectious
conditions compared to AD. Seventeen proteins originating from the
neurological protein panel were also downregulated in the infectious
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conditions compared to AD (Fig. 3). In these groups we found down-
regulation of proteins involved in axonal pathways and brain and
nervous system development, relative to AD patients.
3.2.3. Discriminating protein expression for infectious delirium
Proteins labeled with an asterix in Fig. 3 indicate those proteins that
are significantly dysregulated in infectious delirium compared to all
three other patient groups (non-infectious controls, AD and infections
without delirium). Delirium was accompanied by downregulation of
proteins involved in axonal pathways and upregulation of inflammatory
proteins. The relative expression levels of these proteins are also
depicted in Fig. 5.
3.2.4. Cluster and multivariate analysis
In order to determine which proteins cluster together, and might
thus operate in the same pathway, we analyzed the proteins based on
their expression values using hierarchical clustering. The results are
shown in the hierarchical clustered tree with the corresponding change
in z-score relative to healthy controls in the heatmap in Fig. 6.
From these results, three main clusters can be distinguished. The
first clusters consist of the G protein-coupled receptor ligands C-X-C
motif chemokine 10 (CXCL10) and 11 (CXCL11), which are both
ligands for the CXCR3 receptor. The regulation of these proteins was
however not significantly different in any of the patient comparisons.
Another cluster of proteins that were downregulated in AD and
infectious delirium, but not in infections without delirium were mostly
brain specific proteins and include repulsive guidance molecule A
(RGMA), NBL1, NCAN, THY1, NrCAM, BCAN, cell adhesion molecule
(CADM3) and TNFRSF21. The activator of the NOTCH1 pathway,
DNER, and CST5 also cluster together with this group. Fig. 7 provides
an overview of the possible role of the individual proteins within this
cluster and their relation to synaptic formation and function. The third
cluster of proteins consisted, amongst others, of neurotrophic tyrosine
kinase receptor type 2 (NTRK2) and 3 (NTRK3), of which the first
Fig. 1. Flowchart of the selection of samples from patients with systemic non-neurological infections. CSF: cerebrospinal fluid; LP: lumbar puncture; CNS: central
nervous system.
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shows downregulation in infectious delirium.
Supplemental Fig. 1 presents the results from the principal
component analysis (PCA). Patients with AD and infections without
delirium deviated most from each other. Both components explained
37% of the variance in protein expression.
3.2.5. Age-matched analysis
Since the group of patients with infections without delirium was
Table 1
Baseline characteristics.
Infectious patients AD patients Controls p value
Delirium No delirium
n (% of cohort) 15 (17) 30 (34) 29 (32) 15 (17)
Age (years), mean (SD) 64.2 (17) 49.3 (18) 67.1 (8) 52.2 (18) p < 0.0001□
Sex, male, n (%) 5 (33) 8 (27) 17 (59) 3 (20) ns#
Medical history, n (%):
Malignancy 3 (20) 5 (17) 2 (7) 2 (13) ns#
Cardiovascular disease 6 (40) 4 (13) 4 (14) 3 (20) ns#
Cerebrovascular disease 0 (0) 0 (0) 0 (0) 0 (0) ns#
Hypertension 8 (53) 4 (13) 14 (48) 6 (40) p = 0.014#
Diabetes mellitus 7 (47) 0 (0) 3 (10) 3 (20) p < 0.0001#
Renal disease 4 (27) 2 (7) 0 (0) 0 (0) p < 0.0001#
Psychiatric disease 2 (13) 2 (7) 1 (3) 2 (13) ns#
ICU admission due to sepsis/infection 2 (13) 7 (23) 0 (0) 0 (0) p = 0.010#
Immunocompromised at time of LP 6 (40) 10 (33) 1 (3) 2 (13) p = 0.008#
Charlson comorbidity index (CCI), median (IQR) 2 (1–4) 0 (0–1) 0 (0–1) 0 (0–1) p = 0.010∞
Infectious focus, n (%):
Pulmonary 5 (33) 10 (33)
Upper airway tract 2 (13) 3 (10)
Urinary tract 3 (20) 3 (10)
Abdominal 3 (20) 3 (10)
Skin 0 (0) 3 (10)
Musculoskeletal 0 (0) 2 (7)
Catheter related 1 (7) 2 (7)
Unknown 1 (7) 4 (13)
Vital signs during LP
Temperature (°C), mean (SD) 39.0 (1.0) 38.6 (1.2) ns*
Rate of breathing (/min), median (range) 21 (13–34) 18 (14–34) p = 0.032∞
Heart rate (/min), mean (SD) 88 (13) 92 (16) ns*
Mean arterial pressure (mmHg), mean (SD) 93 (16) 84 (17) ns*
Loss of consciousness, n (%) 10 (67) 6 (20) 0 (0) 0 (0) p < 0.0001#
SOFA score1, mean (SD) 2.9 (1.4) 4.0 (2.8) ns*
APACHE II score1, mean (SD) 14.1 (6.2) 17.6 (7.6) ns*
DOS score, mean (SD) 4.7 (2.5) 0 (0)
CDR scale, n (%):
- 0.5 8 (28)
- 1 18 (62)
- 1–2 3 (10)
Laboratory values
Freezer storage time (years), median (IQR) 3.6 (1.5–5.8) 4.2 (2.6–5.4) 2.4 (1.0–3.7) 1.9 (0.9–3.4) p < 0.0001∞
Leukocytes (*109/l), median (IQR) 11.5 (7.8–15.7) 10.2 (7.6–13.8) 6.3 (5.3–6.8) 6.8 (5.8–8.9) p = 0.0004∞
CRP (mg/l), median (IQR) 94 (37–283) 95 (55–176) 5 (5–5) 5 (4–5) p < 0.0001∞
CSF/plasma albumin ratio2, median (IQR) 8.8 (4.6–17.6) 4.9 (3.1–7.9) 6.1 (5.0–9.4) 6.1 (3.5–7.8) ns
* Independent t-test; □ one-way ANOVA; #Chi-square test; ∞ Kruskal-Wallis test; 1 available for n = 14, 2 available for n = 47.
AD: Alzheimer’s disease; ICU: Intensive Care Unit; LP: lumbar puncture; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology and Chronic
Health Evaluation II; DOS: Delirium Observation Scale; CDR: Clinical Dementia Rating; CRP: C-reactive protein; CSF: cerebrospinal fluid.
Fig. 2. CSF concentration of AD biomarkers in all patient groups. Aβ1-42/ Aβ1-40 ratio: Amyloid β1-42/ Amyloid β1-40 ratio; pTau: phosphorylated Tau-181; Controls:
non-infectious controls; AD: Alzheimer’s disease; ID-: infectious patients without delirium; ID+: infectious patients with delirium; *** p < 0.0001 according to one-
way ANOVA.
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larger (n = 30) and younger (mean age: 49.3 (± 18) years) than the
infectious delirium group (n = 15, mean age: 64.2 (± 17) years), we
performed age-matching through exclusion of fourteen patients in the
infection group without delirium. This resulted in a cohort of 16
patients with a mean age of 64.2 (± 8) years. Many differences in
protein expression compared to AD were still present after
age-matching. Nine proteins were upregulated and the upregulation of
IL6, G-CSF and IL8 were most pronounced. Twenty proteins were
downregulated of which CCL19, CD38, CXCL5 and CXCL6 showed the
strongest downregulation. Fig. 8A–C presents the fold changes before
(on x-axis) and after age-matching (on y-axis). This shows a strong
linear relation suggesting that the trend of fold changes between patient
groups is not severely affected by differences in age. However p-values
shifted due to attenuated statistical power and this resulted in loss of
statistical significance for many especially neurology-related proteins
(Fig. 8D–F). Although trends remained the same, statistical significance
was lost for 29 proteins that overlapped in delirium and AD, and
differed in their expression from the infectious patients without
delirium (Fig. 8H).
3.2.6. Correlation with systemic inflammatory parameters
Supplemental Fig. 2 presents CSF proteins which were significantly
correlated with plasma CRP, as marker of systemic inflammation.
Significant correlations with temperature and blood leukocyte counts
were lost after correction for multiple testing. Of note, none of the
synapse-associated proteins described in Fig. 7 were correlated with
systemic inflammation.
4. Discussion
In this study we evaluated protein expression patterns in CSF of
patients with or without a delirium during a systemic infectious episode
and compared those to samples from patients with AD and uninfected
controls free of neurologic disease in search for overlap in common
pathways linked to inflammation or neurodegeneration. Our key
finding is that we found corresponding protein expression patterns
within the CSF of patients with infectious delirium and patients with
AD, which contrasted to infected patients that did not suffer from
delirium and the controls. This finding supports the hypothesis of an
overlapping pathophysiology for infectious delirium and AD and may
explain the strong epidemiological association between the occurrence
of delirium and unfavorable long-term cognitive sequalae.
A cluster of proteins mostly related to synapse biology was
downregulated in both infectious delirium and AD, in contrast to
healthy controls and infectious patients without delirium. Based on our
results, the most promising markers for future studies into synapse
pathology were NBL1 (which antagonizes the BMP signaling pathway
that regulates synaptic development and strength (Ball et al., 2015; Kim
et al., 2019), THY1 (which functions as stabilizer of neuronal synapses
(Tiveron et al., 1992), NrCAM and TNFRSF21 (both involved in synapse
formation (Kallop et al., 2014; Olsen et al., 2014; Sakurai, 2012) and
the extracellular matrix proteins NCAN and BCAN (essential for
synaptogenesis and neuronal synaptic plasticity (Gottschling et al.,
2019)).
Synapse loss is an early event in AD, preceding neuronal death
(Selkoe, 2002). From all pathological hallmarks, in postmortem brain
tissue synaptic loss correlated best with cognitive dysfunction in AD,
indicating it as important in the pathogenesis (Coleman and Yao, 2003;
DeKosky et al., 1996; Terry et al., 1991). Both amyloid-β and tau, the
well-known AD pathological proteins, contribute substantially to this
synapse loss (Spires-Jones and Hyman, 2014). The data on synaptic loss
in neurodegeneration have resulted in ongoing efforts to discover CSF
markers of synapse degeneration that could assess AD disease
progression in subjects at-risk, even before neurodegeneration or
clinical signs of cognitive decline occur (Lleo et al., 2019). We now
show that not only AD patients show downregulation of synapse-
Fig. 3. Heatmap of differentially expressed proteins. The colors indicate the
change in z-score of the Normalized Protein Expression Units (NPX) values
relative to non-infectious controls. Red shades indicated a downregulation
while blue indicates upregulation compared to controls. The asterix (*) in-
dicates proteins that are significantly differentially regulated in infectious de-
lirium relative to all other diagnosis categories: non-infectious controls,
Alzheimer’s disease (AD) and infections without delirium. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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associated proteins, but patients with infectious delirium share this
feature as well. The CSF amyloid ratios and tau levels in patients with
infectious delirium did not follow the AD pattern, making it less likely
that the synapse-related overlap in AD and delirium was due to
subclinical AD in patients with delirium.
Many of the proteins we report in this synapse-related cluster have
been found to play a role in AD (Ajmo et al., 2010; Lleo et al., 2019;
Morawski et al., 2012; Nikolaev et al., 2009; Satoh et al., 2013;
Wildsmith et al., 2014; Yan et al., 2016; Yang et al., 2013). However, a
recent study showed no differences in CSF concentrations of
extracellular matrix proteins (BCAN and NCAN) between patients with
AD and an age-matched control group (Minta et al., 2019). In delirium
some of these proteins have only recently been discovered by a
proteomic approach (Poljak et al., 2014). In this latter study especially
differences in protein expression between patients with delirium and
AD were assessed. In accordance with our results, NCAN, CADM and
Thy1 showed similar regulation in both groups. However, NrCAM was
downregulated in delirium relative to AD. BCAN was downregulated in
moderate delirium compared to AD and upregulated in mild delirium
compared to AD (Poljak et al., 2014). In our study we did not
distinguish between delirium severities or subtypes. None of the
dysregulated proteins in our cohort were discovered in preoperative
samples from patients who developed postoperative delirium
subsequently in another proteomics study (Westhoff et al., 2015),
which might indicate that synapse loss in delirium patients may not
reflect underlying preclinical neurodegenerative pathology. It is
possible that postoperative delirium develops via different
pathophysiological pathways than infection-induced delirium, since in
addition to systemic inflammation, surgery is often accompanied by risk
factors such as administration of anesthetics, preoperative fasting and
dehydration, coagulation abnormalities, hypothermia and
postoperative pain (Aldecoa et al., 2017).
Despite the recent interest in synapse pathology (Davis et al., 2015;
Jarquin-Valdivia and Major, 2019), the hypothesis that this could be
involved in the pathophysiology of delirium was already postulated in
1913 by Dr. Henry Shaw (Shaw, 1913) and has up to now been studied
mostly in animal models. Using different mice models eliciting
delirium-like cognitive dysfunction, it has been shown that
Fig. 4. Relative protein expression levels of proteins of particular interest. Z-scores of Normalized Protein Expression (NPX) values in non-infectious controls
(Controls), Alzheimer’s disease (AD) patients, infectious patients without delirium (ID−) and infectious patients with delirium (ID+). P-values: *p < 0.05,
**p < 0.001, *** p < 0.0001, according to one-way ANOVA with Bonferroni post-hoc tests.
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inflammatory or traumatic stimuli can cause synaptic loss in the
hippocampus and cortex, which is accompanied by cognitive defects
(Cursano et al., 2020; Moraes et al., 2015). In addition it has been
demonstrated that prior degenerative axonal and synaptic pathology
increases the risk for cognitive deterioration after a systemic
inflammatory challenge even before baseline cognitive impairment has
emerged (Davis et al., 2015). Accordingly, older animals already had
50% lower synapse numbers at baseline (Cursano et al., 2020). This
preexistent neurodegeneration decreases the threshold and might
explain why behavioral deficits are more severely expressed in elderly
patients. These data support a bidirectional interplay in which
preexisting synapse pathology can predispose towards the development
of delirium and new synapse loss can also occur as a consequence of
delirium.
In addition, synaptic loss in neuronal cultures was prevented by
inhibiting pro-inflammatory microglial IL-1β signaling through a IL-1
receptor antagonist (Moraes et al., 2015). Also, it has recently been
shown that prior synaptic loss in mice left them selectively vulnerable
not only to systemic IL-1β-induced acute cognitive dysfunction,
resembling delirium, but also to microglial IL-1β-induced neuronal
hyperexcitability and neuronal death (Skelly et al., 2019). In vivo,
microglial activation is regulated by binding of fractalkine to its
receptor CX3CR1 on microglia (Harrison et al., 1998), among others.
Interestingly, we found upregulation of fractalkine CSF concentrations
in patients with AD and infectious delirium relative to patients with
systemic infections. Fractalkine is a transmembrane protein
predominantly expressed on neurons which can be cleaved to generate
a soluble fragment (Clark et al., 2009; Harrison et al., 1998). Both
fractalkine isoforms can directly regulate microglial activity.
Fractalkine signaling was found to suppress the neuroinflammatory
response by decreasing pro-inflammatory cytokine production
(Cardona et al., 2006; Zujovic et al., 2000) and is therefore important
for CNS homeostasis. Although, fractalkine could be regarded as an
attractive target for therapeutic immunomodulation its precise role in
neurodegeneration is still unclear. On the one hand fractalkine
signaling may be beneficial in amyloid pathology and stroke, while on
the other hand it could also be detrimental in several conditions
including tauopathies, Parkinson’s disease and amyotrophic lateral
sclerosis (Finneran and Nash, 2019). Higher fractalkine mRNA
expression was found in tissue homogenates from human AD brain and
reflected an intermediate disease stage (Strobel et al., 2015). Similarly,
plasma fractalkine levels were significantly higher in patients with mild
to moderate AD than in patients with severe AD (Kim et al., 2008).
Previous CSF studies show contrasting results on fractalkine in AD
(Nordengen et al., 2019; Perea et al., 2018). Our data add the novel
finding of an overlap in fractalkine expression pattern in patients with
infectious delirium and AD.
Loss of microglial homeostatic control is further illustrated by a
shared downregulated expression of CD200R1 in patients with AD and
infectious delirium, relative to infectious patients without delirium.
CD200R1 is, similar to CX3CR1, a membrane-bound molecule
expressed by microglia (Manich et al., 2019). Through binding to its
ligand CD200, which is expressed by neurons, astrocytes and
oligodendrocytes, this receptor inhibits pro-inflammatory microglial
activation. Defects in CD200-CD200R1 signaling during inflammation
produce an exaggerated neuroinflammatory response upon repeated
stimuli. This microglial priming has been related to development of
neurodegenerative diseases (Perry et al., 2007; Perry and Holmes,
Fig. 5. Discriminating protein expression patterns for infectious delirium. Z-scores of Normalized Protein Expression (NPX) values in non-infectious controls
(Controls), Alzheimer’s disease (AD) patients, infectious patients without delirium (ID-) and infectious patients with delirium (ID+). P-values: * p < 0.05, **
p < 0.001, *** p < 0.0001, according to one-way ANOVA with Bonferroni post-hoc tests.
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2014). Histological studies in AD patients have previously shown
reduced expression of both CD200 and CD200R1 (Walker et al., 2009)
and interventions aimed at increasing these levels have been suggested
to have therapeutic potential in neurodegenerative diseases (Ngwa and
Liu, 2019). In delirium, this microglial regulatory pathway has not been
studied previously. Of interest is also the downregulation of caspase-8
(CASP8) in CSF from patients with infectious delirium and AD. This
protease is not only involved in apoptotic cell death but also controls
microglial activation and thus the degree of neuroinflammation
(Burguillos et al., 2011). Post-mortem brain samples from AD patients
have shown significant cytoplasmic expression of activated CASP8
mainly in microglia (Burguillos et al., 2011). To our knowledge, the
association between CASP8 and delirium is a new finding.
Although we found important similarities in CSF protein expression
between infectious delirium and AD, the PCA shows the most
resemblance in protein expression between both infectious patients
groups. This is most likely due to the fact that many proteins within the
used PEA panels are immune system related, leading to an overlapping
expression profile in both infectious groups. Irrespective of the overlap
between the infectious groups, the similarities in protein expression
between infectious delirium and AD provides us with insights in shared
pathophysiological pathways between these two latter groups.
Nine proteins were significantly dysregulated in infectious delirium
relative to the other three patient groups. These included upregulation
of several inflammatory proteins and downregulation of two proteins
involved in neurogenesis: protogenin (PRTG) and disintegrin and
metalloproteinase domain-containing protein 22 (ADAM 22). These
latter have not previously been associated with delirium.
Studies analyzing CSF biomarkers for delirium in patients have
resulted in a wide variety of candidates and sometimes with
inconsistent results. Amyloid-β isoforms, phosphorylated and total tau,
neurotransmitters and hormones, inflammatory proteins, markers for
blood-CSF barrier disruption and neuronal cell death have been studied
(Hall et al., 2018), but the heterogeneity of patients due to many
precipitating factors that may result in delirium, preclude development
of an unifying pathophysiological model of delirium. Nevertheless, the
Fig. 6. Hierarchical cluster dendrogram of proteins with a correlation> 0.85
and at least an average expression value of> 1 in one of the disease groups.
The heatmap shows the corresponding changes in z-scores for Alzheimer’s
disease, infectious delirium and infection without delirium, relative to non-in-
fectious controls. The asterix (*) indicates proteins that are significantly dif-
ferentially regulated in> 1 of the diagnosis groups.
Fig. 7. Overview of protein functions within
the synapse-associated cluster. The
extracellular matrix proteins neurocan core
protein (NCAN) and brevican core protein
(BCAN) form an organized structure called the
perineuronal net, which is vital for
synaptogenesis, synaptic transmission and
synaptic plasticity. Neuronal cell adhesion
molecule (NrCAM), cell adhesion molecule 3
(CADM3), repulsive guidance molecule A
(RGMA) and tumor necrosis factor receptor
superfamily member 21 (TNFRSF21) play a
role in synapse formation. THY1 (CD90)
stabilizes neuronal synapses. Neuroblastoma
suppressor of tumorigenicity (NBL1) is an
antagonist of bone morphogenetic proteins
(BMP) and BMP signaling regulates synaptic
development and strength. Delta and Notch-
like epidermal growth factor-related receptor
(DNER) affects glutamate uptake function
which in turn affects synaptic transmission.
The cells in blue and orange represent neurons.
(For interpretation of the references to colour
in this figure legend, the reader is referred to
the web version of this article.)
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current literature supports the vulnerable brain concept in which
biomarker evidence for both neurodegeneration and neuroinflamma-
tion is associated with delirium, which is in line with findings from this
current study.
Several limitations of this study should be taken into account. Most
importantly, this was a retrospective observational study. Obtaining
CSF is only possible through invasive procedures which makes
prospective sampling from patients with delirium for research purposes
challenging. Several previous studies have overcome this problem by
sampling through spinal anesthetic catheters prior to surgical
procedures. A major drawback from such an approach is that the
sampling is before and not during occurrence of delirium and that in
these patients many different predisposing and co-occurring risk factors
play a role (e.g. use of anesthetics, postoperative pain, use of opioids
and benzodiazepines, etc.) which introduce heterogeneity and impedes
the search for a specific pathogenetic pathway. Our aim was to study
pathophysiological pathways in patients that developed a delirium due
to a systemic infection because of the strong link between systemic
inflammation (and infections) and dementia and the link between
dementia and delirium. We therefore chose a retrospective study design
using biobanked samples. Consequently, this introduces risks of
misclassification, confounding, and pre-analytical differences. In order
to reduce the risk on misclassification we carefully selected the cases
applying strict in- and exclusion criteria. Regarding possible
confounding factors, we were unfortunately not able to include enough
controls or infectious patients with delirium to completely match
Fig. 8. Effect of age-matching on fold changes and p-values of protein expression within patient groups. Fold changes (A-C) and −10log(p-values) (D-F) of com-
parisons of protein expression with infectious patients without delirium before (on x-axis) and after age-matching (on y-axis). Red circles in A-C indicate proteins
which lost significance after age-matching of the infectious patients (FDR-corrected p-value > 0.05, according to paired t-tests). These proteins are depicted in the
right lower quadrant in D-F. Proteins in the right upper quadrant remained significantly different after age-matching. Proteins depicted in the left upper quadrant
became significantly different following age-matching. The composition of the original and age-matched cohort is shown in G. Statistical significant overlap in
protein expression was lost after age-matching for proteins depicted in H. Control: non-infected controls; Infection, no delirium: Infectious patients without delirium;
AD: Alzheimer’s disease; Delirium: infectious delirium. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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patients based on their baseline demographics, despite using a large
CSF biobank. Age is one of such factors that differed between the
included groups. Age-matching infectious patients without delirium to
the infectious cohort with delirium led to loss of statistical significance
of differences in neurology-related protein expression between these
two groups. This was most likely a power issue due to small sample
sizes as we have shown by a strong linear relation between fold changes
before and after age-matching that the trend of fold changes remained
mostly intact following age-matching. As such, our data suggest that
aging was only partially responsible for the differences in protein
expression within the two systemic infection cohorts. Aging is a strong
known risk factor for delirium and combined with our data, synaptic
loss could mediate this. A recent study using transcriptomics on human
brain tissue showed that advancing age was associated with
downregulation of synapses among other processes (González-Velasco
et al., 2020). Our data of a possible interaction between synapse
dysfunction, and loss of homeostatic microglial control precipitating
especially elderly patients to development of delirium warrants further
studies.
Pre-analytical differences were limited to a longer freezer storage
time for samples from AD patients, however since samples did not
undergo previous thawing, we expect the effects on our results limited.
Another disadvantage of the retrospective study design is that
cognitive testing is not routinely performed in patients and therefore
information on cognition in the groups is missing. However, none of the
patients with infections or non-infectious controls had known
neurodegenerative disease (including MCI) at enrollment. This was
corroborated by the analysis of the CSF patterns of amyloid and tau.
Finally, with the PEA technology we used one cannot customize the
panels and these contain only 92 preselected proteins. This may
introduce an important bias and substantially limits the options for
systems biology approaches for pathway analyses. Nevertheless, this
technology is much more cost affordable compared to proteomics and
enabled us to measure over 150 proteins in CSF (using 2 panels) with
high precision and use of very low volume specimens. Since this is a
hypothesis-generating study, our results should be validated using
independent assays and a second validation cohort in future work.
Strengths of our study include that we used CSF specimens taken
during the delirium episode. Compared to most studies where causes of
delirium vary substantially amongst included patients, we were able to
create a relatively homogeneous cohort with only infectious patients as
cases. We included not only infectious patients with and without
delirium but also non-infectious controls and patients with AD.
Previous studies often did not include a control group with systemic
inflammation but no delirium. This increased our ability to investigate
other possible confounding factors that could have accounted for
differences between infectious patients with an acute illness and
outpatient AD patients and test our hypothesis in search of overlapping
pathways underlying infectious delirium and dementia.
In conclusion, this is the first study in humans in vivo indicating that
synapse pathology and loss of homeostatic microglial control are
involved in the pathophysiology of both infectious delirium and AD.
Our data suggests that the synaptopathy and loss of homeostatic mi-
croglial control in patients with delirium were not due to underlying
preclinical AD-like pathology that predisposes to the development of
delirium. Whether these phenomena are indeed key underlying
mechanisms specific to delirium warrants validation in future studies.
Our observations may provide an explanation for the well-known
associations between infection, delirium and the development of
long-term cognitive decline.
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